TABLE 4.
Underweight (n = 22) | Normal (n = 258) | Overweight (n = 75) | Obese (n = 91) | P* | |
---|---|---|---|---|---|
Imaging modality | |||||
ERCP--any | 10 (45) | 121 (47) | 26 (35) | 34 (37) | 0.03 |
No. ERCP | |||||
1 | 6 | 70 | 14 | 18 | |
2 | 1 | 23 | 8 | 10 | |
3 | 1 | 8 | 4 | 3 | |
≥4 | 2 | 20 | 0 | 3 | |
MRCP/MRI | 18 (82) | 218 (84) | 63 (84) | 80 (88) | 0.55 |
CT scan | 10 (45) | 113 (44) | 42 (56) | 46 (51) | 0.07 |
EUS | 2 (9) | 29 (11) | 9 (12) | 12 (13) | 0.59 |
Findings on any imaging | |||||
Focal acute pancreatitis | 2/16 (12) | 28/184 (15) | 9/55 (16) | 14/68 (21) | 0.35 |
Inflammatory changes | 4/17 (24) | 56/186 (30) | 25/56 (45) | 38/69 (55) | 0.0001 |
Enlarged pancreas | 1/16 (6) | 36/185 (19%) | 14/56 (25) | 33/70 (47) | <0.0001 |
Cysts/pseudocysts | 3/18 (17) | 35/236 (15%) | 11/68 (16) | 13/85 (15) | 0.85 |
Peripancreatic inflammation/fat stranding | 2/16 (12) | 54/192 (28) | 28/56 (50) | 28/69 (41) | 0.001 |
Gallstones/sludge | 1/17 (6) | 12/184 (7) | 4/56 (7) | 7/73 (10) | 0.44 |
Pancreatic atrophy | 6/17 (35) | 49/185 (26) | 16/57 (28) | 13/71 (18) | 0.29 |
PD stricture | 7/18 (39) | 56/226 (25) | 9/64 (14) | 12/81 (15) | 0.008 |
PD irregularity | 6/16 (38) | 73/185 (39) | 20/56 (36) | 20/72 (28) | 0.12 |
PD dilatation | 7/16 (44) | 74/184 (40) | 19/57 (33) | 23/73 (32) | 0.12 |
PD stone | 3/14 (21) | 40/205 (20) | 9/57 (16) | 11/67 (16) | 0.42 |
Calcifications | 4/16 (25) | 16/185 (9) | 2/56 (4) | 6/71 (8) | 0.26 |
Abnormal side branches | 6/14 (43) | 57/299 (28) | 12/58 (21) | 17/65 (26) | 0.25 |
Denominators represent data available for each group; data expressed as n (%) unless otherwise specified.
Statistically significant values are in bold.
Cochran-Armitage trend test was used for statistical comparisons.
ERCP indicates, endoscopic retrograde cholangiopancreatography; MRI, Magnetic resonance imaging; MRCP, Magnetic resonance cholangiopancreatography; CT, Computed tomography; EUS, Endoscopic ultrasound; PD, pancreatic duct.